LPTX — Leap Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $12.08m
- -$20.64m
- 18
- 47
- 27
- 21
Annual income statement for Leap Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.5 | 1.5 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 30 | 42.9 | 56.8 | 87 | 70.1 |
| Operating Profit | -28.5 | -41.4 | -56.8 | -87 | -70.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.5 | -40.6 | -54.4 | -81.4 | -67 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -27.5 | -40.6 | -54.6 | -81.4 | -67.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.5 | -40.6 | -54.6 | -81.4 | -67.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -37.6 | -40.6 | -54.6 | -81.4 | -67.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.34 | -4.73 | -4.82 | -2.54 | -1.81 |